bit.bio Overview
- Founded
- 2016
- Status
- Private
- Employees
- 145
- Latest Deal Type
- Series B
- Latest Deal Amount
- $188M
- Investors
- 27
bit.bio General Information
Description
Developer of a cell coding technology designed for a new generation of cell therapies by democratizing access to consistent and functional human cells. The company's platform combines synthetic and stem-cell biology while providing efficient and consistent reprogramming of human cells used in research, drug discovery, and cell therapy, enabling scientists to improve research and drug discovery, lower the cost and extend the application of cell therapies.
Contact Information
Website
www.bit.bio
Formerly Known As
Elpis BioMed, Cambridge Cell Technologies
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Healthcare Technology Systems
Decision/Risk Analysis
Primary Office
- The Dorothy Hodgkin Building
- Babraham Research Campus
- Cambridge CB22 3FH
- England, United Kingdom
+44 01223 000000
bit.bio Timeline
bit.bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series B) | 31-Dec-2021 | $188M | 00000 | 00000 | Completed | Generating Revenue |
| 6. Later Stage VC (Series A) | 28-Feb-2020 | 000.00 | 000.00 | 00000 | Completed | Generating Revenue |
| 5. Grant | 01-Dec-2019 | 00000 | 00.000 | Completed | Generating Revenue | |
| 4. Seed Round | 27-Mar-2019 | 00.000 | 00.000 | 000.00 | Completed | Generating Revenue |
| 3. Seed Round | 16-Nov-2017 | 00000 | 00000 | 00.000 | Completed | Generating Revenue |
| 2. Grant | 01-Aug-2017 | $90.9K | Completed | Generating Revenue | ||
| 1. Accelerator/Incubator | 01-Jan-2017 | Completed | Generating Revenue |
bit.bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | 00,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
| Series B-1 | 0,000,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 00.000 | |
| Series A | 00,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
| Series A | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| Seed | 496,991 | $0.000001 | $8.03 | $8.03 | 1x | $8.03 | 12.66% | |
| Ordinary | 280,010 | $0.000001 | $1.42 | $1.42 | 1x | $1.42 | 7.13% |
bit.bio Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a cell coding technology designed for a new generation of cell therapies by democratizing access to consist
Drug Discovery
Cambridge, United Kingdom
145
As of 2021
00000
0000
0000-00-00
00000000000
00000
0000000
gna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
0000 000000000
Cambridge, United Kingdom
00
As of 0000
000.00
0000
0000-00-00
00000000000
000.00
00 00000
iquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum
0000 000000000
Burnaby, Canada
00
As of 0000
000.00
0000000000
000.00
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialbit.bio Competitors (61)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mogrify | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 000.00 | 00000000000 | 000.00 |
| 00 000000000 | Venture Capital-Backed | Burnaby, Canada | 00 | 000.00 | 0000000000 | 000.00 |
| 00000 000 | Venture Capital-Backed | South San Francisco, CA | 00 | 00000 | 000000000 | 00000 |
| 00000 000000000000 | Venture Capital-Backed | Vancouver, Canada | 00 | 000.00 | 00000000000 | 000.00 |
| 000000000 | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 000.00 | 0000000000 0 | 000.00 |
bit.bio Patents
bit.bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210284960-A1 | Method of generating hepatic cells | Pending | 11-Mar-2020 | 000000000000 |
bit.bio Executive Team (8)
bit.bio Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alan Roemer | Self | Board Member | 000 0000 |
| Florian Schuster | bit.bio | Co-Founder, Chief Corporate Officer & Board Member | 000 0000 |
| Gregory Winter Ph.D | Self | Board Member | 000 0000 |
| Hermann Hauser Ph.D | Self | Chairman | 000 0000 |
| Jason Whitmire Ph.D | BlueYard Capital | Board Member | 000 0000 |
bit.bio Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialbit.bio Investors (27)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Charles River Laboratories | Corporation | Minority | 000 0000 | 000000 0 | |
| Dynamk Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Firstminute Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Good AI Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Harmonix Fund | Venture Capital | Minority | 000 0000 | 000000 0 |